Page 82 - Technology Network News Today

A new study has explored why some patients do not respond to cancer immunotherapy, demonstrating that specific gut bacteria can alter therapy responses and immune signaling in mouse models.

IMAX (NYSE:IMAX – Get Rating) had its price target boosted by Rosenblatt Securities from $25.00 to $27.00 in a research note released on Friday, The Fly reports. Several other equities research analysts have also weighed in on the company. StockNews.com initiated coverage on IMAX in a research report on Thursday, March 16th. They set a […]

Research supports the idea that the window of brain plasticity for some visual tasks extends further than previously thought.

While adding a little water is popularly thought to “open up” the flavor of whisky, a new study indicates there’s a point at which it becomes too much: about 20%.

IMAX (NYSE:IMAX – Get Rating) had its target price increased by Rosenblatt Securities from $25.00 to $27.00 in a research report report published on Friday morning, The Fly reports. IMAX has been the topic of a number of other research reports. The Goldman Sachs Group increased their price target on IMAX from $12.00 to $14.00 […]

IMAX Co. (NYSE:IMAX – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The […]

IMAX (NYSE:IMAX – Get Rating) had its price objective lifted by stock analysts at Rosenblatt Securities from $25.00 to $27.00 in a report released on Friday, The Fly reports. Rosenblatt Securities’ price objective indicates a potential upside of 28.88% from the stock’s current price. IMAX has been the topic of several other research reports. B. […]

Scientists have shown that the same changes in sleep that people with dementia experience are mirrored in dogs with the canine equivalent of dementia, canine cognitive dysfunction syndrome (CCDS).

IMAX (NYSE:IMAX – Get Rating) had its price target increased by analysts at Rosenblatt Securities from $25.00 to $27.00 in a research note issued to investors on Friday, The Fly reports. Rosenblatt Securities’ target price would suggest a potential upside of 35.20% from the company’s previous close. Several other equities analysts have also issued reports […]

Blood clot researchers could benefit from a new device that mimics a human vein, replacing the need for animals for some studies.